SCHEMBL16202046

SCHEMBL16202046

Cc1cc(Oc2ccc(F)cc2)ncn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
MAPK14 Q16539 2/20 0.47
BRAF P15056 1/20 0.47
KDR P35968 1/20 0.47
TNNI3K Q59H18 1/20 0.47
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MRGPRX1 Q96LB2 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
HTT P42858 1/20 0.42
CYP1A2 P05177 3/20 0.41
CYP2C19 P33261 3/20 0.41
NPC1 O15118 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12825874 0.82 KDR (0.47) SMN1; SMN2CASP3SENP8SENP7SENP6
SCHEMBL4795745 0.82 SMN1; SMN2 (0.46) SMN1; SMN2CASP3SENP8SENP7SENP6
SCHEMBL4795754 0.82 SMN1; SMN2 (0.48) SMN1; SMN2CASP3SENP8SENP7SENP6
SCHEMBL16202043 0.82 MAPK1 (0.50) SMN1; SMN2CASP3SENP8SENP7SENP6
SCHEMBL753276 0.81 SMN1; SMN2 (0.61) SMN1; SMN2CASP3SENP8SENP7SENP6
SCHEMBL1415748 0.79 L3MBTL1 (0.45) SMN1; SMN2CASP3SENP8SENP7SENP6
SCHEMBL18362139 0.76 MEN1 (0.42) SMN1; SMN2CASP3SENP8SENP7SENP6
SCHEMBL8277605 0.75 DRD1 (0.50) SMN1; SMN2CASP3SENP8SENP7SENP6
SCHEMBL4800515 0.75 SMN1; SMN2 (0.40) SMN1; SMN2CASP3SENP8SENP7SENP6
SCHEMBL18362140 0.75 MEN1 (0.45) SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2016-09-01 US disclosed
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-26 US disclosed
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi BASF SE (DE) 2016-05-26 US disclosed
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-05 US disclosed
US-9271501-B2 Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors BASF SE (DE) 2016-03-01 US disclosed
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI SNX1, DPM1, SNU13 SMN1; SMN2 2653/4885CASP3 3330/4885SENP8 960/4885
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI DPM1, CROCC, SNX1 SMN1; SMN2 3486/4885CASP3 1719/4885SENP8 486/4885
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi DPM1, CROCC, SNX1 SMN1; SMN2 3486/4885CASP3 1719/4885SENP8 486/4885
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB SMN1; SMN2 2724/4885CASP3 3257/4885SENP8 3133/4885
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB SMN1; SMN2 2724/4885CASP3 3257/4885SENP8 3133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.